HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07546929

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Housey Healthcare ULC (from the registry)
Registry
  • NCT NCT07546929
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07546929. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-03 (actual); primary completion 2026-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Intervention (Drug)
HP-211
Intervention (Drug)
Placebo
Lead sponsor
Housey Healthcare ULC (class: industry)

Record details

Record id
cardio:ct-nct07546929
Content hash
f4da427df58dda5067c288549e58e2830b2d5e368e6923e449e6337c5c4919d0